- Enters 2018 as a Public Company with Solid Financial Position Following Successful Completion of Merger with Inotek Pharmaceuticals and Subsequent Follow-on Offering - - Multiple Milestones Expected ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced participation in a consortium selected to receive funding from ...
Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic ...
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) ...
NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product ...
CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its ...
License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional ...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs. Virica and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results